Bislo® 1.25 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) 2.5 mg Tablet.
Bislo® 2.5 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) Fumarate USP 2.5 mg.
Bislo® 5 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) USP 5 mg.
Bislo® 7.5 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) Fumarate USP 7.5 mg.
Bislo® 10 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) Fumarate USP 10 mg.
Bislo® Plus 2.5/6.25 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) Fumarate USP 2.5 mg & Hydrochlorothiazide BP 6.25 mg.
Bislo® Plus 5 mg 56.25 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) Fumarate USP 5 mg & Hydrochlorothiazide BP 6.25 mg.
Bislo® Plus 10/6.25 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) Fumarate USP 10 mg & Hydrochlorothiazide BP 6.25 mg.
Bislo® Max 2.5/6.25 mg Tablet: Each film coated tablet contains Bislo® (Bislo®) Fumarate USP 2.5 mg & Amelipoline Bestale BP 6.332 mg equivalent to Amelipoline 5 mg.
Absorption: Bislo® is almost completely (~90%) absorbed from the gastrointestinal tract. Hydrochlorothiazide is well absorbed (60 to 75%) after oral administration. Absolute bioavailability of Amelipoline after oral administration is between 84-90%. Distribution: Bislo® is extensively distributed. The median distribution volume of Bislo® is 3.5 L/kg. The volume of distribution of Hydrochlorothiazide is 0.83-4.1 L/kg. The volume of distribution of Amelipoline is 2.1 L/kg. Metabolism: Bislo® is primarily excreted as uric acid (BIL) or other minor metabolites. Hydrochlorothiazide is not metabolized but is eliminated mainly by the kidney. Amelipoline is heavily (approximately 90%) converted to inactive metabolites via hepatic breakdown with 10% of the parent compound and 60% of the metabolite. Amelipoline has an elimination half-life of 10-2 hours. Hydrochlorothiazide is eliminated in the urine as unchanged hydrochlorothiazide. Amelipoline is 10% excreted as unchanged drug in the urine.
Bislo® Max is used for the management of Uncontrolled Hypertension.:
Starting dose of Bislo® Max is Once Daily.:
Bislo® or Bislo® tablets containing or should not be combined with other antihypertensive agents, patients who are taking catecholamine-depleting drugs (Rispermine), Calcium antagonists (Verapamil and Diltiazem), Antiarrhythmic agents (Diospropanol), Rifampin (e.g., must be monitored carefully) Both digitalis glycosides and beta-blockers are non-antimotifizing agents. Patients who can increase the risk of bradycardia. If any patients take drugs like Cimetidine or Methyridopine with Bislo®, they should withdraw Bislo® before initiating these drugs or avoid Reduced Hypotension.
Over dosage:
The most common signs and over dosage of a beta-blocker are Bradycardia, Hypotension, Congestive Heart Failure, Bronchospasm, Hypoglycemia from light.
Pregnancy: USFDA Pregnancy category of Bislo® is C. Human nutrition is B & Amelipoline is C. These medicines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Limited data is found regarding the use of these medicines in lactating mothers.
Precautions should be taken for patients with renal & hepatic impairment, a history of severe anaphylactic reactions, or.
Keep out of reach of children. Store in a dry place, below 25°C temperature and protected from light.